Ann: Trading Halt, page-36

Proof/evidence is a minor difference? When we were at 4 cents a year ago it was still pending proof/evidence. Minor set back to refine the results (23/03/2017) with new ovarian results 09/01/2018 and additional results 06/03/2018. It is now just commercialisation to tap into anpossibly 5.2 billion $ market

Patent issued 07/08/2017 (AUS), 02/02/2018 (Japan)
Lung cancer 15/5/2017. Publication for peer review 08/08/2017...

The price in March 2017 was hammered by now corrected results. Time is cash and cash burn for biotechs can be hard.

BD1 no only has been busy working they in my thought have already added significant value which is not yet factored into the share price. That might make a cap raising a lot easier.

Market supported the cap raising 11/07/2017 and share purchase plan 04/08/2017.

I do not suspect my shares will be 1 cent again. Surprise the list of results and achievements in the last 12 months makes you think otherwise. I do have a positive outlook I admit and acknowledge. I try to be sceptical but cannot really see your reasons. Care to elaborate? Not having a dig- honest. Biotechs are easy to loose money in of course. Only a few actual make it.